Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhong, Qing ^a   Rüschoff, Jan H ^a   Guo, Tiannan ^b   Gabrani, Maria ^c   Schüffler, Peter J ^b   Rechsteiner, Markus ^a   Liu, Yansheng ^b   Fuchs, Thomas J ^d   Rupp, Niels J ^a   Fankhauser, Christian ^a   Buhmann, Joachim M ^b   Perner, Sven ^e   Poyet, Cédric ^a   Blattner, Miriam ^f   Soldini, Davide ^a   Moch, Holger ^a   Rubin, Mark A ^f   Noske, Aurelia ^a   Rüschoff, Josef ^g   Haffner, Michael C ^h   Jochum, Wolfram ⁱ   Wild, Peter J ^a   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c IBM RESEARCH ZURICH   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g Targos Molecular Pathology GmbH   (Germany)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

AGED; BIOLOGY; CANCER STAGING; COPY NUMBER VARIATION; ENDOMETRIUM TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; STOMACH TUMOR;

AGED; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84962780858     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24146     Document Type: Article

References (43)

1. Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72, 4875-4882 (2012
2. Marusyk, A., Almendro, V., & Polyak, K. Intra-Tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer. 12, 323-334 (2012
3. Longo, D. L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 366, 956-957 (2012
4. Cancer Genome Atlas Research, N., et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013
5. Janiszewska, M., et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat. Genet. 47, 1212-1219 (2015
6. Wolff, A. C., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18-43 (2007
7. Reid, A. H., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489-1495 (2010
8. Reid, A. H., et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod. Pathol. 25, 902-910 (2012
9. Krohn, A., et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 181, 401-412 (2012
10. Fuchs, T. J., & Buhmann, J. M. Computational pathology: challenges and promises for tissue analysis. Comput. Med. Imag. Grap. 35, 515-530 (2011
11. Zhong, Q., Busetto, A. G., Fededa, J. P., Buhmann, J. M., & Gerlich, D. W. Unsupervised modeling of cell morphology dynamics for time-lapse microscopy. Nat. Methods. 9, 711-713 (2012
12. Cima, I., et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc. Natl. Acad. Sci. USA. 108, 3342-3347 (2011
13. Beck, A. H., et al. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci. Transl. Med. 3, 108ra113 (2011
14. Yuan, Y., et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci. Transl. Med. 4, 157ra143 (2012
15. Wilkens, L., et al. Detection of chromosomal aberrations in well-differentiated hepatocellular carcinoma by bright-field in situ hybridization. Mod. Pathol. 15, 470-475 (2002
16. Schuffler, P. J., et al. TMARKER: A free software toolkit for histopathological cell counting and staining estimation. J. Pathol. Inform. 4, S2 (2013
17. Duda, R. O., & Hart, P. E. Use of the Hough transformation to detect lines and curves in pictures. Commun. ACM. 15, 11-15 (1972
18. Cortes, C., & Vapnik, V. Support-Vector Networks. Mach. Learn. 20, 273-297 (1995
19. Krohn, A., et al. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod. Pathol. 27, 1612-1620 (2014
20. Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer. 11, 289-301(2011
21. Haffner, M. C., et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918-4922 (2013
22. Carver, B. S., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009
23. Lotan, T. L., et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod. Pathol. 26, 587-603 (2013
24. Noske, A., et al. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. Exp. Mol. Pathol. 98, 47-54 (2015
25. Carpenter, A. E., et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006
26. Swedlow, J. R., Goldberg, I. G., & Eliceiri, K. W., & Consortium, O. M. E. Bioimage informatics for experimental biology. Annu. Rev. Biophys. 38, 327-346 (2009
27. Held, M., et al. CellCognition: time-resolved phenotype annotation in high-Throughput live cell imaging. Nat. Methods. 7, 747-754 (2010
28. Peng, H., Bateman, A., Valencia, A., & Wren, J. D. Bioimage informatics: a new category in Bioinformatics. Bioinformatics. 28, 1057 (2012
29. Neumann, B., et al. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature. 464, 721-727 (2010
30. Jaqaman, K., et al. Robust single-particle tracking in live-cell time-lapse sequences. Nat. Methods. 5, 695-702 (2008
31. Stenzinger, A., et al. Quantitative analysis of diagnostic guidelines for HER2-status assessment. J. Mol. Diagn. 14, 199-205 (2012
32. Barbieri, C. E., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012
33. Guo, T., et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat. Med. 21, 407-413 (2015
34. Liu, Y., et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-Acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol. Cell. Proteomics. 13, 1753-1768 (2014
35. Mortezavi, A., et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 17, 1111-1121 (2011
36. Blattner, M., et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia. 16, 14-20 (2014
37. Haldrup, C., et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J. Clin. Oncol. 31, 3250-3258 (2013
38. Kristensen, H., et al. Hypermethylation of the GABRE ~ miR-452 ~ miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 20, 2169-2181 (2014
39. Ikenberg, K., et al. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J. Pathol. 234, 239-252 (2014
40. Ruschoff, J., et al. HER2 testing in gastric cancer: a practical approach. Mod. Pathol. 25, 637-650 (2012
41. Tomlins, S. A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 310, 644-648 (2005
42. Park, K., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 12, 590-598 (2010
43. Chang, C.-C., & Lin, C.-J. LIBSVM: A library for support vector machines. ACM Trans. Intell. Syst. Technol. 2, 1-27 (2011